Apolipoprotein E and its receptors in Alzheimer’s disease: pathways, pathogenesis and therapy. Bu G. Nat Rev Neurosci. 2009; 10(5):333344.
ApoE and Aβ in Alzheimer’s disease: accidental encounters or partners? Neuron. Kanekiyo T, Xu H, Bu G. 2014; 81(4):740754.
Apolipoprotein E as a Therapeutic Target in Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence. Yamazaki Y, Painter MM, Bu G, Kanekiyo T. CNS Drugs. 2016; 30(9):773789.
Apolipoprotein E and Alzheimer’s disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins. Huynh TV, Davis AA, Ulrich JD, Holtzman DM. J Lipid Res. 2017; 58(5):824836.
Apolipoprotein E, Receptors, and Modulation of Alzheimer’s Disease. Zhao N, Liu CC, Qiao W, Bu G. Biol Psychiatry. 2018; 83(4):347357.
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G. Nat Rev Neurol. 2019; 15(9):501518.
Practical considerations for choosing a mouse model of Alzheimer’s disease. Jankowsky JL, Zheng H. Mol Neurodegener. 2017; 12(1):89.
Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight. Shi Y, Holtzman DM. Nat Rev Immunol. 2018; 18(12):759772.
A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward. Belloy ME, Napolioni V, Greicius MD. Neuron. 2019; 101(5):820838.
ApoE4: an emerging therapeutic target for Alzheimer’s disease. Safieh M, Korczyn AD, Michaelson DM. BMC Med. 2019; 17(1):64.
The role of APOE in cerebrovascular dysfunction. Tai, L. M., Thomas, R., Marottoli, F. M., Koster, K. P., Kanekiyo, T., Morris, A. W., & Bu, G. Acta neuropathologica. 2016; 131(5), 709723.
Therapeutic approaches targeting Apolipoprotein E function in Alzheimer’s disease. Williams T, Borchelt DR, Chakrabarty P. Mol Neurodegener. 2020 Jan 31;15(1):8.
Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease. Najm R, Jones EA, Huang Y. Mol Neurodegener. 2019 Jun 11;14(1):24.
Genetics ignite focus on microglial inflammation in Alzheimer’s disease. Malik M, Parikh I, Vasquez JB, Smith C, Tai L, Bu G, LaDu MJ, Fardo DW, Rebeck GW, Estus S. Mol Neurodegener. 2015 Oct 5;10:52.